Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA3 | P07451 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591197 | 0.84 | MIF (0.60) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL30267413 | 0.84 | MIF (0.60) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL6687148 | 0.82 | MAOB (0.76) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL3363272 | 0.81 | KDM4E (0.62) | MAOBALDH1A1HPGDKDM4ECA12 | |
| SCHEMBL13823093 | 0.81 | CA12 (0.53) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL23506385 | 0.81 | MAOB (0.54) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL592979 | 0.80 | MAOB (0.69) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL30790593 | 0.80 | MAOB (0.69) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL1366230 | 0.79 | ALDH1A1 (0.81) | MAOBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL52650 | 0.79 | ALDH1A1 (0.81) | MAOBALDH1A1HPGDKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10254287-B2 | Protein fluorescent nanoparticles and methods of synthesis thereof | UNIVERSITY OF CONNECTICUT (US) | 2019-04-09 | — | — | US | claimed |
| US-20170023580-A1 | PROTEIN FLUORESCENT NANOPARTICLES AND METHODS OF SYNTHESIS THEREOF | UNIVERSITY OF CONNECTICUT | 2017-01-26 | — | — | US | claimed |
| US-12509435-B2 | Compounds for selective binding to estrogen receptors alpha/beta relative to GPER/GPR30 and methods of treating disease states and conditions mediated through these receptors | UNM RAINFOREST INNOVATIONS (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250067734-A1 | Fluorescent Cellulose Particles | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-118119848-A | Fluorescent cellulose particles | 旭化成株式会社 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023089972-A1 | FLUORESCENT CELLULOSE PARTICLES | 旭化成株式会社 | 2023-05-25 | — | — | WO | disclosed |
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
| US-11150358-B2 | Radiation dosimetry sol or gel and radiation dosimeter comprising same as material for radiation dosimetry | RIKEN (JP) | 2021-10-19 | — | — | US | disclosed |
| EP-3314257-B1 | CELL TRACKING REAGENTS AND THEIR METHODS OF USE | LIFE TECHNOLOGIES CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-108608703-B | Polymer sheet | 北欧化工公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200333474-A1 | RADIATION DOSIMETRY SOL OR GEL AND RADIATION DOSIMETER COMPRISING SAME AS MATERIAL FOR RADIATION DOSIMETRY | RIKEN (JP) | 2020-10-22 | — | — | US | disclosed |
| US-7018805-B2 | α-Amylase assay and uses thereof | VICAM L.P. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1599744-A2 | SELF-INDICATING RADIATION ALERT DOSIMETER | JP LABORATORIES, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1585971-A3 | a-AMYLASE ASSAY AND USES THEREOF | VICAM, L.P. (US) | 2005-11-10 | — | — | EP | disclosed |
| EP-1585971-A2 | a-AMYLASE ASSAY AND USES THEREOF | VICAM, L.P. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004077097-A2 | SELF-INDICATING RADIATION ALERT DOSIMETER | JP LABORATORIES INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004020970-A2 | α-AMYLASE ASSAY AND USES THEREOF | VICAM, L.P. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20040043116-A1 | Alpha-amylase assay and uses thereof | WATERS TECHNOLOGIES CORPORATION | 2004-03-04 | — | — | US | disclosed |
| US-6362008-B1 | Generic signalling mechanism for detection of analytes | WATERS TECHNOLOGIES CORPORATION | 2002-03-26 | — | — | US | disclosed |
| WO-1999032886-A1 | GENERIC SIGNALLING MECHANISM FOR DETECTION OF ANALYTES | VICAM, L.P. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509435-B2 | Compounds for selective binding to estrogen receptors alpha/beta relative to GPER/GPR30 and methods of treating disease states and conditions mediated through these receptors | GPER1, ESR2, ESRRG | MAOB 1131/4885ALDH1A1 2514/4885HPGD 2581/4885 |
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | MAOB 1225/4885ALDH1A1 1983/4885HPGD 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.